https://pharmadevicenews.com/a-simple-injection-cut-a-key-alzheimers-protein-by-73-can-arrowhead-turn-that-into-cognitive-benefit/ PharmaDeviceNews en 2026-10-16T16:50:08+00:00 A simple injection cut a key Alzheimer’s protein by 73%. Can Arrowhead turn that into cognitive benefit? Adam Boxer, Alzheimer’s disease, ARO-MAPT, ARO-MAPT-SC, Arrowhead Pharmaceuticals, Biogen, CELIA Study, Christopher Anzalone, Diranersen, frontotemporal dementia, Ionis Pharmaceuticals, MAPT, Progressive Supranuclear Palsy, RNA interference, Tau Protein, TRiM, University of California San Francisco https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Alzheimers-generic.webp https://pharmadevicenews.com/pilatus-biosciences-doses-first-hong-kong-patient-in-plt012-liver-cancer-trial/ PharmaDeviceNews en 2026-10-16T16:45:40+00:00 Pilatus Biosciences doses first Hong Kong patient in PLT012 liver cancer trial Cancer Research Institute, CD36, FDA, hepatocellular carcinoma, Hong Kong Department of Health, Ludwig Institute for Cancer Research, Novotech, Pilatus Biosciences, PLT012, Prince of Wales Hospital, Raven Lin, Stephen Chan, The Chinese University of Hong Kong https://pharmadevicenews.com/wp-content/uploads/2026/07/AbelZetas-C-CAR031-Nature-study-strengthens-the-case-for-armored-CAR-T-in-advanced-liver-cancer-e1785037227142.webp https://pharmadevicenews.com/ironfists-tamrada-more-than-doubles-survival-in-preclinical-pancreatic-cancer-model/ PharmaDeviceNews en 2026-10-16T16:41:42+00:00 Ironfist’s Tamrada more than doubles survival in preclinical pancreatic cancer model copper-64, EANM 2026, Ironfist Therapeutics, Jeffrey Cleland, Johns Hopkins University, Lutetium-177, Mukul Agarwal, pancreatic ductal adenocarcinoma, PD-1 inhibitors, radiopharmaceuticals, Sakura Minami, Tamrada, theranostics, Tumor-Associated Macrophages https://pharmadevicenews.com/wp-content/uploads/2026/05/ClearNote-Health-to-present-Avantect-pancreatic-cancer-test-validation-data-at-ASCO-2026-e1779559031969.webp https://pharmadevicenews.com/akamis-bio-completes-33-patient-ng-350a-rectal-cancer-trial-after-early-50-response/ PharmaDeviceNews en 2026-10-16T15:18:00+00:00 Akamis Bio completes 33-patient NG-350A rectal cancer trial after early 50% response Akamis Bio, Capecitabine, CD40 agonist, CEDAR, chemoradiotherapy, circulating tumor DNA, colorectal cancer, Fast Track designation, FDA, FORTRESS, Mismatch Repair-Proficient Colorectal Cancer, NG-350A, Oliver Rosen, Rectal Cancer, T-SIGn https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-14-2026-09_35_09-AM-e1789358748685.webp https://pharmadevicenews.com/coyas-als-trial-has-enrolled-120-patients-why-is-it-extending-coya-302-treatment-before-results-arrive/ PharmaDeviceNews en 2026-10-16T15:14:50+00:00 Coya’s ALS trial has enrolled 120 patients. Why is it extending COYA 302 treatment before results arrive? ALSFRS-R, ALSTARS, amyotrophic lateral sclerosis, Arun Swaminathan, COYA 302, Coya Therapeutics, CTLA-4 Ig, Dr. Reddy’s Laboratories, Fast Track designation, FDA, Fred Grossman, frontotemporal dementia, interleukin-2, regulatory T cells https://pharmadevicenews.com/wp-content/uploads/2026/01/neurological-basis-of-amyotrophic-lateral-sclerosis.webp https://pharmadevicenews.com/one-blood-sample-68000-possible-pathogens-can-delve-bio-speed-up-infection-diagnosis/ PharmaDeviceNews en 2026-10-16T14:54:40+00:00 One blood sample, 68,000 possible pathogens: Can Delve Bio speed up infection diagnosis? Brad Murray, CAP, Charles Chiu, CLIA, Delve Bio, Delve Decide, Delve Detect, Delve Detect Plasma, IDWeek 2026, immunocompromised patients, infectious disease diagnostics, metagenomic next-generation sequencing, molecular diagnostics, University of California San Francisco https://pharmadevicenews.com/wp-content/uploads/2026/07/Blood-test.webp https://pharmadevicenews.com/nemolizumab-improved-itching-and-sleep-for-a-year-in-young-children-can-galderma-expand-its-fda-label/ PharmaDeviceNews en 2026-10-16T06:52:53+00:00 Nemolizumab improved itching and sleep for a year in young children. Can Galderma expand its FDA label? ARCADIA, atopic dermatitis, Christophe Piketty, Dupilumab, Dupixent, FDA, Galderma, IL-31 Receptor Alpha, Interleukin-31, Lawrence Eichenfield, Nemluvio, nemolizumab, Pediatric Dermatology Research Alliance, PeDRA 2026 https://pharmadevicenews.com/wp-content/uploads/2026/03/Galderma-presents-pediatric-nemolizumab-findings-at-AAD-2026-as-regulatory-case-builds-for-under-12-label-e1774759149703.webp https://pharmadevicenews.com/gilead-is-betting-nearly-1-9bn-on-masked-cancer-drugs-what-makes-virs-technology-different/ PharmaDeviceNews en 2026-10-16T04:39:20+00:00 Gilead is betting nearly $1.9bn on masked cancer drugs. What makes Vir’s technology different? Amunix Pharmaceuticals, Astellas Pharma, cancer immunotherapy, dAIsY, Flavius Martin, Gilead Sciences, Marianne De Backer, PRO-XTEN, Sanofi, solid tumors, T-cell engagers, Vir Biotechnology, VIR-5500, VIR-5525, VIR-5818 https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp https://pharmadevicenews.com/the-fda-rejected-tab-cel-twice-can-ataras-third-review-finally-deliver-approval/ PharmaDeviceNews en 2026-10-16T04:34:22+00:00 The FDA rejected tab-cel twice. Can Atara’s third review finally deliver approval? ALLELE, allogeneic T-cell therapy, Atara Biotherapeutics, Cokey Nguyen, EBVALLO, Epstein-Barr virus, European Medicines Agency, FDA, Pierre Fabre Laboratories, Post-Transplant Lymphoproliferative Disease, Tab-cel, tabelecleucel https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/sareptas-rna-therapy-reaches-the-nucleus-in-myotonic-dystrophy-models-can-it-restore-muscle-function/ PharmaDeviceNews en 2026-10-15T06:55:30+00:00 Sarepta’s RNA therapy reaches the nucleus in myotonic dystrophy models. Can it restore muscle function? Alpha-v Beta-6 Integrin, ARO-DM1, Arrowhead Pharmaceuticals, DMPK, FSHD, Louise Rodino-Klapac, Muscleblind-Like Proteins, Myotonic Dystrophy Type 1, Oligonucleotide Therapeutics Society, RNA interference, Sarepta Therapeutics, SRP-1001, SRP-1003 https://pharmadevicenews.com/wp-content/uploads/2026/07/ARTHEx-Biotech-publishes-peer-reviewed-CNS-data-for-ATX-01-in-myotonic-dystrophy-e1785149513306.webp https://pharmadevicenews.com/cyted-healths-endosign-detects-barretts-esophagus-with-90-sensitivity-in-us-study/ PharmaDeviceNews en 2026-10-15T06:52:03+00:00 Cyted Health’s EndoSign detects Barrett’s esophagus with 90% sensitivity in US study American College of Gastroenterology, Barrett’s esophagus, CAP, CLIA, Cyted Health, DETECT-ME, DNA Methylation, EndoSign, esophageal adenocarcinoma, FDA, Marcel Gehrung, Nick Shaheen, Non-Endoscopic Screening, University of North Carolina https://pharmadevicenews.com/wp-content/uploads/2026/07/EvoEndo-broadens-access-to-FDA-cleared-single-use-endoscopy-platform-e1785238730935.webp https://pharmadevicenews.com/jcrs-enzyme-therapy-reaches-kuwait-can-crossing-the-blood-brain-barrier-change-hunter-syndrome-care/ PharmaDeviceNews en 2026-10-15T06:47:01+00:00 JCR’s enzyme therapy reaches Kuwait. Can crossing the blood-brain barrier change Hunter syndrome care? blood-brain barrier, enzyme replacement therapy, Hunter syndrome, Iduronate-2-Sulfatase, IZCARGO, J-Brain Cargo, JCR Pharmaceuticals, JR-141, Kuwait, Mucopolysaccharidosis Type II, pabinafusp alfa, Taiba Middle East, United Arab Emirates https://pharmadevicenews.com/wp-content/uploads/2026/07/JCR-Pharmaceuticals-and-Taiba-prepare-UAE-commercial-pathway-for-IZCARGO-e1784691506530.webp https://pharmadevicenews.com/can-estrellas-eb103-challenge-established-car-t-therapies-in-b-cell-lymphoma/ PharmaDeviceNews en 2026-10-15T05:37:38+00:00 Can Estrella’s EB103 challenge established CAR-T therapies in B-cell lymphoma? ARTEMIS T-cell Therapy, B-cell non-Hodgkin lymphoma, Baylor Scott and White Research Institute, CD19, Cheng Liu, EB103, Estrella Immunopharma, Eureka Therapeutics, FDA, Intermountain Health, LDS Hospital, Oregon Health and Science University, STARLIGHT-1, UC Davis Comprehensive Cancer Center, University Hospitals Cleveland Medical Center https://pharmadevicenews.com/wp-content/uploads/2026/07/Estrella-Immunopharma-reports-durable-EB103-responses-and-starts-expansion-stage-dosing-e1784990540893.webp https://pharmadevicenews.com/fda-expands-anktiva-approval-to-papillary-only-bladder-cancer-after-bcg-failure/ PharmaDeviceNews en 2026-10-15T05:33:30+00:00 FDA expands ANKTIVA approval to papillary-only bladder cancer after BCG failure Altor BioScience, ANKTIVA, Bacillus Calmette-Guérin, carcinoma in situ, FDA, IL-15, ImmunityBio, nogapendekin alfa inbakicept, non-muscle-invasive bladder cancer, Papillary Bladder Cancer, Patrick Soon-Shiong, QUILT-3.032, Richard Adcock, urology https://pharmadevicenews.com/wp-content/uploads/2026/05/AstraZenecas-Imfinzi-wins-FDA-approval-in-BCG-naive-high-risk-bladder-cancer-e1780028582395.webp https://pharmadevicenews.com/aptars-nasal-vaccine-device-is-now-ce-marked-could-it-help-bring-more-needle-free-vaccines-to-market/ PharmaDeviceNews en 2026-10-15T05:29:08+00:00 Aptar’s nasal vaccine device is now CE marked. Could it help bring more needle-free vaccines to market? Alex Theodorakis, Aptar Pharma, AptarGroup, CastleVax, CE marking, CVAX-01, European Medical Device Regulation, European Union, Intranasal Vaccines, LuerVax, Nektaria Karavas, Spray Divider, vaccine delivery https://pharmadevicenews.com/wp-content/uploads/2026/10/Aptar-LuerVax-and-Spray-Divider-receive-CE-marking-under-EU-MDR-e1792042109297.webp https://pharmadevicenews.com/altay-therapeutics-closes-37m-series-a-for-fshd-treatment-dx5057/ PharmaDeviceNews en 2026-10-15T04:32:29+00:00 Altay Therapeutics closes $37m Series A for FSHD treatment DX5057 Ali Ozes, Altay Therapeutics, Biogen New Ventures, delpacibart braxlosiran, DUX4, DX5057, facioscapulohumeral muscular dystrophy, Fountain Healthcare Partners, FSHD, Global BioAccess Fund, HealthCap, James Breitmeyer, Novartis, Pappas Capital, SOLVE FSHD, Sound Bioventures https://pharmadevicenews.com/wp-content/uploads/2026/01/pharmaceutical-compounds-and-clinical-tools.webp https://pharmadevicenews.com/celltrions-injectable-infliximab-has-taken-over-32-share-in-major-european-markets-whats-driving-adoption/ PharmaDeviceNews en 2026-10-15T04:27:47+00:00 Celltrion’s injectable infliximab has taken over 32% share in major European markets. What’s driving adoption? Celltrion, Crohn’s Disease, CT-P13 SC, Gionata Fiorino, Infliximab, Irina Blumenstein, LIBERTY-CD, LIBERTY-UC, Peter Irving, Remsima IV, Remsima IV Liquid, Remsima SC, Steqeyma, UEG Week 2026, ulcerative colitis, Yuflyma, Zymfentra https://pharmadevicenews.com/wp-content/uploads/2026/08/IBS-treatment-e1788212354211.webp https://pharmadevicenews.com/takedas-new-narcolepsy-drug-cuts-cataplexy-by-up-to-89-can-orzeyful-transform-treatment/ PharmaDeviceNews en 2026-10-15T04:24:10+00:00 Takeda’s new narcolepsy drug cuts cataplexy by up to 89%. Can ORZEYFUL transform treatment? Emmanuel Mignot, FDA, FirstLight, MHLW, Narcolepsy Type 1, NMPA, Orexin Receptor 2, ORZEYFUL, Oveporexton, RadiantLight, sleep medicine, TAK-861, Takeda Pharmaceutical https://pharmadevicenews.com/wp-content/uploads/2026/08/Takeda-ORZEYFUL-wins-FDA-approval-for-adult-narcolepsy-type-1-treatment-e1786073313875.webp